MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

Inclusion Criteria: * Ability to understand the purpose of the study, provide signed and dated informed consent, and able to comply with all procedures * In Japan, if a subject is \< 20 years, the written informed consent from his/her parent or guardian will be required in addition to the subject's written consent * Male or female subjects aged greater than or equal to (\>=) 18 years * Life expectancy \>= 12 weeks as judged by the Investigator * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at trial entry * Disease must be measurable with at least 1 uni dimensional measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. * Adequate hematological, hepatic and renal function as defined in the protocol * Effective contraception for both male and female subjects if the risk of conception exists Other protocol-defined inclusion criteria could apply. Exclusion Criteria: * Concurrent treatment with non-permitted drugs and other interventions * Anticancer treatment within 28 days before the start of trial treatment, for example cyto reductive therapy, radiotherapy (with the exception of palliative radiotherapy delivered in a normal organ-spearing technique), immune therapy, or cytokine therapy * Major surgery within 28 days before the start of trial treatment (prior diagnostic biopsy is permitted) * Systemic therapy with immunosuppressive agents within 7 days before the start of trial treatment; or use of any investigational…